Search the Newsreel

Ocugen (OCGN) Q2 2026 Earnings Call Transcript

Image source: The Motley Fool. DATE Thursday, Aug. 6, 2026 at 8:30 a.m. ET CALL PARTICIPANTS Chairman, Chief Executive Officer, and Co-Founder - Shankar MusunuriChief Financial Officer - Rita Johnson-GreeneExecutive Vice President of Commercial and Business Development - Abhi GuptaChief Medical Officer - Mohamed …

Ocugen Inc. stock falls Thursday, underperforms market

Ocugen Inc. (OCGN) stock experienced a 3.57% decline on Thursday, closing at $1.35. This fall occurred despite a positive trading session for the broader market, with both the S&P 500 and Dow Jones Industrial Average seeing gains. The decrease in Ocugen's stock price broke …

Ocugen Inc. stock rises Tuesday, outperforms market

Ocugen Inc. (OCGN) shares increased by 4.58% to $1.37 on Tuesday, marking its third consecutive day of gains. This rise occurred despite a general downturn in the stock market, with both the S&P 500 Index and Dow Jones Industrial Average experiencing declines. The stock's …

Research Analysts Issue Forecasts for Ocugen Q3 Earnings

HC Wainwright has revised its Q3 2026 EPS forecast for Ocugen to a loss of $0.07 per share, down from $0.06, and anticipates continued losses through FY2028, with profitability expected in FY2029. Despite missing the consensus EPS estimate for its latest quarter, Ocugen's revenue …

What is Noble Financial's Forecast for Ocugen Q3 Earnings?

Noble Financial has revised its Q3 2026 earnings forecast for Ocugen (NASDAQ:OCGN) to a loss of $0.06 per share, down from a previous estimate of a $0.05 loss. The firm also projects losses of $0.07 per share for Q4 2026 and $0.26 for the …

Hennion & Walsh Asset Management Inc. Purchases 1,553,672 Shares of Ocugen, Inc. $OCGN

Hennion & Walsh Asset Management Inc. significantly increased its stake in Ocugen, Inc. by 121.7% in the second quarter, now holding 2.83 million shares valued at approximately $4.33 million. This comes as Ocugen advances its pipeline with FDA clearance for a Phase 3 trial …

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen (OCGN) reported a wider-than-expected loss of 7 cents per share in Q2 2026, primarily due to increased research and development expenses, despite a slight beat on revenues which rose 8.4% to $1.5 million. The company's stock fell 3% following the announcement, reflecting an …

Ocugen (NASDAQ:OCGN) Downgraded by Wall Street Zen to "Sell"

Wall Street Zen has downgraded Ocugen (NASDAQ:OCGN) from "Hold" to "Sell," despite a broader "Moderate Buy" consensus among analysts with a $9.50 average price target. The company recently reported a wider-than-expected quarterly loss of $0.07 per share, though revenue surpassed estimates at $1.49 million, …

Ocugen Q2 Earnings Call Highlights

Ocugen reported progress across its late-stage ophthalmology pipeline in its Q2 earnings call, including FDA clearance for a Phase III study of OCU410 in geographic atrophy and an RMAT designation. The company plans to file three biologics license applications (BLAs) by 2028 and expects …

Ocugen Inc (OCGN) Stock News Today

Ocugen (NASDAQ:OCGN) Posts Earnings Results, Misses Estimates By $0.02 EPS

Ocugen, Inc. 2026: Revenue $1.49M, EPS ($0.07) — 10-Q Summary

Ocugen, Inc. reported its 2026 quarterly results with revenue of $1.49M, a net loss of ($24.88M), and a diluted loss per share of ($0.07). The company highlighted clinical milestones, including Phase 3 enrollment completion for OCU400 and dosing completion for OCU410ST, alongside multiple regulatory …

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Ocugen, Inc. reported its second quarter 2026 financial results, highlighting significant advancements in its gene therapy programs for blindness diseases. Key updates include FDA clearance for OCU410 Phase 3 trial in geographic atrophy, RMAT designation for OCU410, and a binding term sheet for OCU400 …

Ocugen (NASDAQ: OCGN) raises $112.5M via converts as losses hit $44.1M

Ocugen (NASDAQ: OCGN), a gene therapy biotechnology company, reported a net loss of $44.1 million for the first half of 2026 and $24.9 million for Q2 2026. Despite raising $112.5 million in net proceeds from a $130.0 million convertible senior notes offering and increasing …

Informe de resultados de Ocugen: supera previsiones de ingresos en el segundo trimestre de 2026, pero amplía pérdidas

Ocugen reports $1.49M Q2 revenue, $0.07 loss per share and $100.4M cash as of June 30, 2026

Ocugen reported second-quarter 2026 results, with collaborative arrangement revenue of $1.49 million and a net loss of $0.07 per share. The company held $100.4 million in cash as of June 30, 2026, and completed a $130.0 million convertible senior notes offering, extending its cash …

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen (OCGN) reported a Q2 loss of $0.07 per share, missing the Zacks Consensus Estimate of a $0.05 loss, though its revenue of $1.49 million surpassed estimates by 6.29%. Despite beating revenue expectations in three of the last four quarters, the company has consistently …

Ocugen (OCGN) Earnings Date and Reports 2026

Ocugen Q2 2026 Earnings Preview

* Ocugen (OCGN [https://seekingalpha.com/symbol/OCGN]) is scheduled to announce Q2 earnings results on Thursday, August 6th, before market open. * The consensus EPS Estimate is -$0.05 [https://seekingalpha.com/symbol/OCGN/earnings/estimates] and the consensus Revenue Estimate is $0.89M (-35.0% Y/Y). * Over the last 1 year, OCGN has beaten …

Ocugen Inc expected to post a loss of 5 cents a share - Earnings Preview

Ocugen Inc is projected to report a loss of 5 cents per share according to an earnings preview. The article, sourced from Reuters via TradingView News, provides this financial forecast for the company.

Ocugen Inc. stock rises Monday, outperforms market

Ocugen Inc. (OCGN) stock increased by 1.63% on Monday, closing at $1.25, while the broader market also saw gains with the S&P 500 and Dow Jones Industrial Average rising. Despite this increase, the company's stock remains 54.13% below its 52-week high of $2.73, which …

FDA grants OCU410 regenerative medicine advanced therapy designation for geographic atrophy

Ocugen's gene therapy, OCU410, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating geographic atrophy secondary to dry age-related macular degeneration. This designation, supported by positive Phase II data showing a significant reduction in GA lesion growth, provides benefits like …

Ocugen to present its gene therapy platform at August 2026 investor conferences.

Ocugen, a biotech company specializing in gene therapies for blindness, will present its modifier gene therapy platform at two investor conferences in August 2026. The presentations will include a panel discussion at the Oppenheimer Biotech Summit and a fireside chat at the Canaccord Growth …

Ocugen to Participate in Upcoming August Investor Conferences

MALVERN, Pa., July 31, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the Company will present on its innovative modifier gene therapy platform at upcoming investor conferences …

Ocugen (NASDAQ: OCGN) plans 250M-share authorization boost tied to notes

Ocugen is seeking stockholder approval to increase its authorized common stock by 250 million shares, from 390 million to 640 million, at a special meeting on September 21, 2026. This increase is necessary to provide flexibility for future equity financing, business combinations, and to …

Ocugen Wins FDA RMAT Designation For OCU410 In Dry AMD- Related Geographic Atrophy

(RTTNews) - Ocugen, Inc. (OCGN), a biotechnology company developing gene therapies for blinding diseases, announced that the U.S. FDA has granted Regenerative Medicine Advanced Therapy (RMAT) status to OCU410 for the treatment of Geographic atrophy in secondary to dry age-related macular degeneration (dAMD). Geographic …

BlackRock (OCGN holder) discloses 8.0% beneficial stake in Ocugen common stock

BlackRock, Inc. has disclosed a beneficial ownership of 8.0% in Ocugen, Inc. common stock, totaling 26,952,492 shares. This information comes from a Schedule 13G SEC filing, indicating that BlackRock holds sole voting power over 26,625,805 shares and sole dispositive power over all 26,952,492 shares, …

Ocugen Inc. stock falls Wednesday, underperforms market

Ocugen Inc. (OCGN) stock fell 4.03% to $1.19 on Wednesday, underperforming the broader market. This marked the stock's second consecutive day of losses, as the S&P 500 Index and Dow Jones Industrial Average also experienced significant declines.

Ocugen Receives RMAT Designation for OCU410 for Treatment of Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration

Ocugen has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its gene therapy OCU410, intended for treating geographic atrophy secondary to dry age-related macular degeneration. This designation is based on positive Phase 2 clinical data showing efficacy and a favorable safety …

Ocugen's OCU410 Gene Therapy Wins FDA RMAT Designation for Geographic Atrophy

Ocugen's OCU410, a one-time AAV gene therapy for geographic atrophy (GA) secondary to dry age-related macular degeneration, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA. This designation aims to expedite development and review for serious conditions with unmet needs, supported by …

A one-time treatment for geographic atrophy gains FDA RMAT status

Ocugen's investigational gene therapy OCU410 has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for treating geographic atrophy secondary to dry age-related macular degeneration. This designation was granted based on positive Phase 2 clinical data showing significant efficacy and a favorable safety …

Ocugen Q2 Results: Earnings call set for Aug 6 to discuss financials

Ocugen, Inc. will host a conference call and live webcast on August 6, 2026, at 8:30 a.m. ET to discuss its second-quarter 2026 financial results and provide a business update. The company, which is developing gene therapies for blindness diseases, will issue a pre-market …

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Ocugen, Inc. will host a conference call and live webcast on Thursday, August 6, 2026, at 8:30 a.m. ET to discuss its second quarter 2026 financial results and provide business updates. The company, a biotechnology leader in gene therapies for blindness, will issue a …